Contact Us
Drug Search Results
More Filters [+]

Gemigliptin

Alternative Names: gemigliptin, lc15-0444
Latest Update: 2024-07-24
Latest Update Note: News Article

Product Description

Mechanisms of Action: DPP4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Colombia | Dominican Republic | Ecuador | India | Jordan | Korea | Mexico | Peru | Philippines | Russia | Ukraine

Approved Indications: None

Known Adverse Events: None

Company: LG
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Gemigliptin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Heart Failure, Chronic|Type 2 Diabetes|Weight Gain|Hyperglycemia|Kidney Failure, Chronic|Hypoglycemia|Heart Failure, Diastolic

Phase 3: Type 2 Diabetes|Dyslipidemia|Kidney Diseases

Phase 1: Healthy Volunteers|Other|Type 2 Diabetes|Malnutrition|General Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CR121038

P4

Recruiting

Type 2 Diabetes

2024-12-31

B-1712/438-004

P4

Recruiting

Type 2 Diabetes|Heart Failure, Chronic|Heart Failure, Diastolic|Hypoglycemia|Hyperglycemia|Kidney Failure, Chronic|Weight Gain

2023-10-31

LG-GLCL001

P3

Unknown status

Type 2 Diabetes

2022-05-30

62%
LG-GLCL003

P1

Unknown status

Healthy Volunteers

2022-02-28

28%

Recent News Events

Date

Type

Title

07/24/2024

News Article

 M8 Pharmaceuticals, an Acino company, Signs Exclusive Agreement with LG Chem for Novel Treatments for Type 2 Diabetes and Osteoarthritis in Latin America

04/09/2024

PubMed

 Improvement effect of gemigliptin on salivary gland dysfunction in exogenous methylglyoxal-injected rats.

03/02/2024

PubMed

 Gemigliptin, a potent selective dipeptidyl peptidase 4 inhibitor, protects endothelial progenitor cells by oxidative stress via caspase-3 dependent pathway.

02/05/2024

PubMed

 In-lab synthesized turn-off fluorescence sensor for estimation of Gemigliptin and Rosuvastatin polypill appraised by Spider diagram, AGREE and whiteness metrics.

02/28/2023

News Article

 M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavoglifozin) for Brazil and Mexico

12/06/2022

News Article

 Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030

02/25/2022

News Article

 Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions